Neuro-ophthalmology

Neuro-ophthalmology is an academically-oriented subspecialty that merges the fields of neurology and ophthalmology, often dealing with complex systemic diseases that have manifestations in the visual system. Neuro-ophthalmologists initially complete a residency in either neurology or ophthalmology, then do a fellowship in the complementary field. Since diagnostic studies can be normal in patients with significant neuro-ophthalmic disease,[1] a detailed medical history and physical exam is essential, and neuro-ophthalmologists often spend a significant amount of time with their patients.

Common pathology referred to a neuro-ophthalmologist includes afferent visual system disorders (e.g. optic neuritis, optic neuropathy, papilledema, brain tumors or strokes) and efferent visual system disorders (e.g. anisocoria, diplopia, ophthalmoplegia, ptosis, nystagmus, blepharospasm and hemifacial spasm). The largest international society of neuro-ophthalmologists is the North American Neuro-Ophthalmological Society (NANOS),[2] which organizes an annual meeting and publishes the Journal of Neuro-Ophthalmology. Neuro-ophthalmologists are often faculty at large university-based medical centers. Patients often have co-existing disease in other fields (rheumatology, endocrinology, oncology, cardiology, etc.), thus the neuro-ophthalmologist is often a liaison between the ophthalmology department and other departments in the medical center.[3]

Description

Neuro-ophthalmology focuses on diseases of the nervous system that affect vision, control of eye movements, or pupillary reflexes. Neuro-ophthalmologists often see patients with complex multi-system disease and “zebras” are not uncommon. Neuro-ophthalmologists are often active teachers in their academic institution, and the first four winners of the prestigious Straatsma American Academy of Ophthalmology teaching awards were neuro-ophthalmologists.[4] Most neuro-ophthalmologists are passionate about their discipline and report high job satisfaction, stating that they think the field continues to be both fascinating and challenging. Neuro-ophthalmology is mostly non-procedural, however, neuro-ophthalmologists may be trained to perform eye muscle surgery to treat adult strabismus, optic nerve fenestration for idiopathic intracranial hypertension, and botulinum injections for blepharospasm or hemifacial spasm.

Two neuro-ophthalmology fellows of Andrew G. Lee published reasons why they chose to pursue the discipline:[5]

"The neuro-ophthalmologist is often the sub-specialty that others turn to when the etiology of visual decline is in question. They are often uniquely suited to provide a global and comprehensive perspective to any complex medical, neurologic, ophthalmologic, or neurosurgical case. A neuro-ophthalmology patient has often already seen 2, if not 3 or more other specialists by the time they arrive at our door. We particularly enjoy the sense of satisfaction, medical accomplishment, and difference we can make in patient's lives when able to discover a diagnosis and treat the condition.

What makes the neuro-ophthalmologist unique is the global viewpoint of the integration and interaction of complex and systemic disorders on visual function. There is no “routine day” for us in neuro-ophthalmology clinic as there is always an interesting patient from which we can learn. Any day can hold a combination of corneal, retinal, optic nerve, rheumatologic, neurologic, infectious, or neurosurgical variety."

Notable neuro-ophthalmologists

Frank B. Walsh was one a pioneer of neuro-ophthalmology, helping to popularize and develop the field. Walsh was born in Oxbow, Saskatchewan in 1895 and earned a degree for University of Manitoba in 1921. He joined the Wilmer Ophthalmological Institute at Johns Hopkins University and began organizing Saturday morning neuro-ophthalmology conferences. Walsh compiled the first neuro-ophthalmology textbook, which was published in 1947 and has been updated over the years by generations of his students.[6]

The future of neuro-ophthalmology

Doctors have been decreasing the time spent with a patient due to economic pressures, the use of nonphysicians, and increasing reliance on laboratory tests. Neuro-ophthalmology has been affected more so than other specialties due to the complexity of the patients and the time required to do a neuro-ophthalmic history and physical exam.[4] Additionally, the current medical reimbursement system rewards quantity of service (performing assembly line procedures) rather than quality of service (making a correct diagnosis, patient education, and counseling), and seeing complex patients is not adequately recognized.

Improved functional neuroimaging is paving the way for better understanding, assessment, and management of many neurologic and neuro-ophthalmologic conditions. As our understanding of neuroscience evolves, neuro-ophthalmologists are becoming increasingly better at treatment, rather than only diagnosis, and novel therapies are emerging to treat traditionally vision-devastating disease.[7] For example, clinical trials began in February 2014 to use gene therapy to treat Leber hereditary optic neuropathy,[8] which is one of the first uses of gene therapy in the central nervous system. Progress has also been made in understanding retinal ganglion cell regeneration and in re-establishing synaptic connections from the optic nerve to the brain,[1] more than in other regions of the central nervous system.[9][10] One of the goals of the National Institutes of Health is to use the visual system as a window to understand neural plasticity and regenerative medicine in the central nervous system,[11] an area of neuroscience that has a promising future and is intimately intertwined with neuro-ophthalmology.

The financial environment for academic neuro-ophthalmologists must be addressed so that there is the clinical infrastructure to treat patients, assess and implement emerging technologies and treatments, and train the next generation of neuro-ophthalmologists. Given the direction of ophthalmic and neurologic research, it is imperative to continue to have a vibrant academic neuro-ophthalmologic community for the future.

References

  1. 1 2 Lessell, S (Apr 2000). "What can we expect in neuro-ophthalmology in the next century?". Archives of ophthalmology 118 (4): 553–4. doi:10.1001/archopht.118.4.553. PMID 10766142.
  2. ↑ "North American Neuro-Ophthalmology Society". North American Neuro-Ophthalmology Society Home Page. Retrieved 28 September 2014.
  3. ↑ McDonnell, Peter (11/1/2004). "Is neuro-ophthalmology in jeopardy?". Ophthalmology Times 29 (21): 4. Check date values in: |date= (help)
  4. 1 2 Frohman, LP (Sep 2008). "The human resource crisis in neuro-ophthalmology.". Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 28 (3): 231–4. doi:10.1097/wno.0b013e318185e084. PMID 18769291.
  5. ↑ Spitze, A; Al-Zubidi, N; Lam, P; Yalamanchili, S; Lee, AG (October 2014). "Neuro-ophthalmology as a career.". Indian journal of ophthalmology 62 (10): 1013–4. doi:10.4103/0301-4738.146007. PMID 25449937.
  6. ↑ Angelucci, Diane. "Groundbreaking neuro-ophthalmologist honored". EyeWorld. Retrieved 28 September 2014.
  7. ↑ Newman, SA (Jun 2012). "Interventional neuro-ophthalmology: not an oxymoron.". Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 32 (2): 177–84. doi:10.1097/wno.0b013e318256638e. PMID 22617746.
  8. ↑ Lam, BL; Feuer, WJ; Schiffman, JC; Porciatti, V; Vandenbroucke, R; Rosa, PR; Gregori, G; Guy, J (Apr 1, 2014). "Trial end points and natural history in patients with G11778A Leber hereditary optic neuropathy : preparation for gene therapy clinical trial.". JAMA ophthalmology 132 (4): 428–36. doi:10.1001/jamaophthalmol.2013.7971. PMID 24525545.
  9. ↑ Watanabe, M; Fukuda, Y (Nov 2002). "Survival and axonal regeneration of retinal ganglion cells in adult cats.". Progress in retinal and eye research 21 (6): 529–53. doi:10.1016/s1350-9462(02)00037-x. PMID 12433376.
  10. ↑ Xia, Y; Nawy, S; Carroll, RC (Nov 7, 2007). "Activity-dependent synaptic plasticity in retinal ganglion cells.". The Journal of neuroscience : the official journal of the Society for Neuroscience 27 (45): 12221–9. doi:10.1523/jneurosci.2086-07.2007. PMID 17989288.
  11. ↑ "NEI Audacious Goal Initiative". National Eye Institute. Retrieved 28 September 2014.

External links

This article is issued from Wikipedia - version of the Monday, December 21, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.